Journal of Materials Science: Materials in Medicine

, Volume 21, Issue 9, pp 2691–2699 | Cite as

Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer

  • Naveen K. Thakral
  • Alok R. Ray
  • Dipak K. Majumdar


COX-2 inhibitors have demonstrated beneficial effects in colorectal cancer. The purpose of this study was to prepare and evaluate the colon specific microspheres of COX-2 inhibitors using valdecoxib as a model drug. Mucoadhesive core microspheres were prepared using chitosan as polymer and entrapped within Eudragit S 100 for colon targeting. FTIR spectrum of selected, coated microspheres showed peaks of valdecoxib at 3377, 3250, 1334 and 1155 cm−1. XRD showed amorphous character and DSC showed depressed broad endotherm of valdecoxib at 169.07°C, which may be attributed to dilution effect by the amorphous polymer. The coated microspheres were spherical with an average size of 90 μm. Storage of the microspheres at 40°C/75% relative humidity for 6 months indicated no significant drug degradation. The coated microspheres did neither release the drug in acidic pH of stomach (pH 1.2) nor in small intestinal pH between 5 to 6.8, and the release started at pH 7.4, indicting perfect colonic delivery. The coated microspheres pretreated with phosphate buffer pH 7.4 for 30 min, when applied to mucosal surface of freshly excised goat colon, showed good mucoadhesion. The drug release at pH 7.4 and good mucoadhesive property of the microspheres make the system ideal for colonic delivery.


Chitosan Drug Release Liquid Paraffin Valdecoxib Mucoadhesive Polymer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Tattersal MHN, Thomas H. Recent advances: oncology. Br Med J. 2005;318:445–8.Google Scholar
  2. 2.
    Pisani P, Bray F, Parkin DM. Estimates of the world wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97:72–81.CrossRefPubMedGoogle Scholar
  3. 3.
    Kune S, Kune GA, Watson LF. The Melbourne Colorectal Cancer Study: incidence findings by age, sex, site, migrants and religion. Int J Epidemiol. 1986;15:483–93.CrossRefPubMedGoogle Scholar
  4. 4.
    Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48:4399–404.PubMedGoogle Scholar
  5. 5.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241–6.PubMedGoogle Scholar
  6. 6.
    Thun MJ, Namboodiri MM, Health CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Eng J Med. 1991;325:1593–6.CrossRefGoogle Scholar
  7. 7.
    Craven PA, Thornburg K, DeRubertis FR. Sustained increase in the proliferation of rat colonic mucosa during chronic treatment with aspirin. Gastroenterology. 1988;94:567–75.PubMedGoogle Scholar
  8. 8.
    Thun MJ, Henley SJ, Patrono C. Non steroidal anti inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Nat Cancer Inst. 2002;94:252–66.PubMedGoogle Scholar
  9. 9.
    Chan TA. Non steroidal anti inflammatory drugs, apoptosis and colon cancer chemoprevention. Lancet Oncol. 2002;3:166–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Finckh A, Aronson MD. Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann Internal Med. 2005;142:212–4.Google Scholar
  11. 11.
    Bartalsky A. Salicylazobenzoic acid in ulcerative colitis. Lancet. 1982;319:960–4.CrossRefGoogle Scholar
  12. 12.
    Riley SA, Turnberg LA. Sulphasalazine and aminosalicylate in the treatment of inflammatory bowl disease. Q J Med. 1990;75:561–2.Google Scholar
  13. 13.
    Gazzaniga A, Iamartina P, Maffione G, Sangal ME. Oral delayed release system for colonic specific delivery. Int J Pharm. 1994;108:77–83.CrossRefGoogle Scholar
  14. 14.
    Ashford M, Fell J, Attwood D, Sharma H, Woodhead P. In vitro investigation into the suitability of pH dependent polymer for colonic targeting. Int J Pharm. 1993;95:193–9.CrossRefGoogle Scholar
  15. 15.
    Hori M, Onishi H, Machida Y. Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. Int J Pharm. 2005;297:223–4.PubMedGoogle Scholar
  16. 16.
    Jain D, Panda AK, Majumdar DK. Eudragit S100 entrapped Insulin microspheres for oral delivery. AAPS Pharm Sci Tech. 2005;06:E100–7.CrossRefGoogle Scholar
  17. 17.
    Marvola M, Nykanen P, Rautio S, Isonen N, Autere AM. Enteric polymer as binder and coating material in multiple unit site-specific drug delivery system. Eur J Pharm Sci. 1999;7:259–67.CrossRefPubMedGoogle Scholar
  18. 18.
    Rahman Z, Kohli K, Khar RK, Ali M, Charoo NA, Shamsher AA. Characterization of 5-fluorouracil microspheres for colonic delivery. AAPS Pharm Sci Tech. 2006;7(2):E1–9.CrossRefGoogle Scholar
  19. 19.
    Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003;6:33–66.PubMedGoogle Scholar
  20. 20.
    Fatima A, Asghar L, Chandran S. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharm Sci. 2006;9(3):327–38.Google Scholar
  21. 21.
    Kramer A, Turk S, Vrecer F. Statistical optimization of diclofenac sodium sustained release pellets coated with polymethacrylic films. Int J Pharm. 2003;256:43–52.CrossRefGoogle Scholar
  22. 22.
    Meyer JH, Dressman J, Fink AS, Amidon G. Effect of size and density on gastric emptying of indigestible solids. Gastroenterology. 1985;89:805–13.PubMedGoogle Scholar
  23. 23.
    Rodriguez M, Vila-Jato JL, Torres D. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J Control Release. 1998;55:67–77.CrossRefPubMedGoogle Scholar
  24. 24.
    Rathbone MJ, Hadgraft J, Roberts MS. Modified release drug delivery technology. New York: Marcel Dekker Inc.; 2003.Google Scholar
  25. 25.
    Lehr CM, Bowstra JA, Tukker JJ, Junginger HE. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat. J Control Release. 1990;13:51–62.CrossRefGoogle Scholar
  26. 26.
    ICH Harmonised Tripartite Guideline for Stability Testing of New Drug Substances and Products.Google Scholar
  27. 27.
    Gibaldi M. Biopharmaceutics & clinical pharmacokinetics. 3rd ed. Phidelphia: Lea Febiger; 1984.Google Scholar
  28. 28.
    Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci. 1969;58:1253–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Higuchi T. Mechanism of sustained action medication. J Pharm Sci. 1963;52:1145–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation: I—Theoretical considerations. Ind Eng Chem. 1931;23:923–31.CrossRefGoogle Scholar
  31. 31.
    Bourne DW. Pharmacokinetics. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics. 4th ed. New York: Marcel Dekker Inc.; 2002. p. 67–92.Google Scholar
  32. 32.
    Chuch HR, Zia H, Rhodes CP. Optimization of sotalol floating and bioadhesive extended release tablet formulations. Drug Dev Ind Pharm. 1995;21:1725–47.CrossRefGoogle Scholar
  33. 33.
    Peppas NA. Analysis of fickian and non-fickian drug release from polymers. Pharm Acta Helv. 1985;60:110–1.PubMedGoogle Scholar
  34. 34.
    Akbuga J. Preparation and evaluation of controlled release of furosemide microspheres by spherical crystallization. Int J Pharm. 1989;53:99–105.CrossRefGoogle Scholar
  35. 35.
    Jain D, Panda AK, Majumdar DK. Insulin loaded Eudragit S100 microspheres for oral delivery: preliminary in vitro studies. J Biomed Appl. 2006;21:195–211.CrossRefGoogle Scholar
  36. 36.
    Peppas NA, Burim PA. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. J Control Release. 1985;2:257–75.CrossRefGoogle Scholar
  37. 37.
    Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive. Biomacromol. 2008;9:1837–42.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Naveen K. Thakral
    • 1
  • Alok R. Ray
    • 1
    • 2
  • Dipak K. Majumdar
    • 3
  1. 1.Centre for Biomedical EngineeringIndian Institute of Technology DelhiNew DelhiIndia
  2. 2.Biomedical Engineering UnitAll India Institute of Medical ScienceNew DelhiIndia
  3. 3.Department of PharmaceuticsDelhi Institute of Pharmaceutical Sciences and Research, Formerly College of Pharmacy, University of DelhiNew DelhiIndia

Personalised recommendations